This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 20/06/2013
SPC Fortum 1g Injection


Go to top of the page
1. Name of the medicinal product

Fortum® for Injection 1 g


Go to top of the page
2. Qualitative and quantitative composition

Fortum for Injection: Vials contain 1g ceftazidime (as pentahydrate) with sodium carbonate (118mg per gram of ceftazidime).


Go to top of the page
3. Pharmaceutical form

Powder for solution for injection


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Fortum is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).

• Nosocomial pneumonia

• Broncho-pulmonary infections in cystic fibrosis

• Bacterial meningitis

• Chronic suppurative otitis media

• Malignant otitis externa

• Complicated urinary tract infections

• Complicated skin and soft tissue infections

• Complicated intra-abdominal infections

• Bone and joint infections

• Peritonitis associated with dialysis in patient on CAPD.

Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (TURP).

The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria (see sections 4.4 and 5.1).

Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.


Go to top of the page
4.2 Posology and method of administration

Posology

Table 1: Adults and children ≥ 40 kg

Intermittent Administration

Infection

Dose to be administered

Broncho-pulmonary infections in cystic fibrosis

100 to 150 mg/kg/day every 8 h, maximum 9 g per day1

Febrile neutropenia

2 g every 8 h

Nosocomial pneumonia

Bacterial meningitis

Bacteraemia*

Bone and joint infections

1-2 g every 8 h

Complicated skin and soft tissue infections

Complicated intra-abdominal infections

Peritonitis associated with dialysis in patients on CAPD

Complicated urinary tract infections

1-2 g every 8 h or 12 h

Per-operative prophylaxis for transurethral resection of prostate (TURP)

1 g at induction of anaesthesia, and a second dose at catheter removal

Chronic suppurative otitis media

1 g to 2 g every 8 h

Malignant otitis externa

Continuous infusion

Infection

Dose to be administered

Febrile neutropenia

Loading dose of 2 g followed by a continuous infusion of 4 to 6 g every 24 h1

Nosocomial pneumonia

Broncho-pulmonary infections in cystic fibrosis

Bacterial meningitis

Bacteraemia*

Bone and joint infections

Complicated skin and soft tissue infections

Complicated intra-abdominal infections

Peritonitis associated with dialysis in patients on CAPD

1In adults with normal renal function 9 g/day has been used without adverse effects. *When associated with, or suspected to be associated with, any of the infections listed in 4.1.

Table 2: Children < 40 kg

Infants and toddlers >2 months and children <40 kg

Infection

Usual dose

Intermittent Administration

 

Complicated urinary tract infections

100-150 mg/kg/day in three divided doses, maximum 6 g/day

 

Chronic suppurative otitis media

 

Malignant otitis externa

 

Neutropenic children

150 mg/kg/day in three divided doses, maximum 6 g/day

 

Broncho-pulmonary infections in cystic fibrosis

 

Bacterial meningitis

 

Bacteraemia*

 

Bone and joint infections

100 – 150 mg/kg/day in three divided doses, maximum 6 g/day

 

Complicated skin and soft tissue infections

 

Complicated intra-abdominal infections

 

Peritonitis associated with dialysis in patients on CAPD

Continuous Infusion

 

Febrile neutropenia

Loading dose of 60-100 mg/kg followed by a continuous infusion 100-200 mg/kg/day, maximum 6 g/day

 

Nosocomial pneumonia

 

Broncho-pulmonary infections in cystic fibrosis

 

Bacterial meningitis

 

Bacteraemia*

 

Bone and joint infections

 

Complicated skin and soft tissue infections

 

Complicated intra-abdominal infections

 

Peritonitis associated with dialysis in patients with CAPD

Neonates and infants ≤ 2 months

Infection

Usual dose

Intermittent Administration

 

Most infections

25-60 mg/kg/day in two divided doses1

1In neonates and infants ≤ 2 months, the serum half life of ceftazidime can be three to four times that in adults.

*Where associated with, or suspects to be associated with, any of the infections listed in section 4.1.

Paediatric population

The safety and efficacy of Fortum administered as continuous infusion to neonates and infants ≤ 2 months has not been established.

Elderly

In view of the age related reduced clearance of ceftazidime in elderly patients, the daily dose should not normally exceed 3 g in those over 80 years of age.

Hepatic impairment

Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment. There are no study data in patients with severe hepatic impairment (see also section 5.2). Close clinical monitoring for safety and efficacy is advised.

Renal impairment

Ceftazidime is excreted unchanged by the kidneys. Therefore, in patients with impaired renal function, the dosage should be reduced (see also section 4.4).

An initial loading dose of 1 g should be given. Maintenance doses should be based on creatinine clearance:

Table 3: Recommended maintenance doses of Fortum in renal impairment – intermittent infusion

Adults and children ≥ 40 kg

Creatinine clearance Ml/min

Approx. serum creatinine µmol/l(mg/dl)

Recommended unit dose of Fortum (g)

Frequency of dosing (hourly)

50-31

150-200

(1.7-2.3)

1

12

30-16

200-350

(2.3-4.0)

1

24

15-6

350-500

(4.0-5.6)

0.5

24

<5

>500

(>5.6)

0.5

48

In patients with severe infections the unit dose should be increased by 50% or the dosing frequency increased. In children the creatinine clearance should be adjusted for body surface area or lean body mass.

Children < 40 kg

Creatinine clearance (ml/min)**

Approx. serum creatinine* µmol/l(mg/dl)

Recommended individual dose mg/kg body weight

Frequency of dosing (hourly)

50-31

150-200

(1.7-2.3)

25

12

30-16

200-350

(2.3-4.0)

25

24

15-6

350-500

(4.0-5.6)

12.5

24

<5

>500

(>5.6)

12.5

48

*The serum creatinine values are guideline values that may not indicate exactly the same degree of reduction for all patients with reduced renal function.

** Estimated based on body surface area, or measured.

Close clinical monitoring for safety and efficacy is advised.

Table 4: Recommended maintenance doses of Fortum in renal impairment – continuous infusion

Adults and children ≥ 40 kg

Creatinine clearance (ml/min)

Approx. Serum creatinine µmol/l (mg/dl)

Frequency of dosing (hourly)

50-31

150-200

(1.7-2.3)

Loading dose of 2 g followed by 1 g to 3 g /24 hours

30-16

200-350

(2.3-4.0)

Loading dose of 2 g followed by 1 g /24 hours

≤ 15

> 350

(>4.0)

Not evaluated

Caution is advised in dose selection. Close clinical monitoring for safety and efficacy is advised.

Children < 40 kg

The safety and effectiveness of Fortum administered as continuous infusion in renally impaired children < 40 kg has not been established, Close clinical monitoring for safety and efficacy is advised.

If continuous infusion is used in children with renal impairment, the creatinine clearance should be adjusted for body surface area or lean body mass.

Haemodialysis

The serum half-life during haemodialysis ranges from 3 to 5 h.

Following each haemodialysis period, the maintenance dose of ceftazidime recommended in the below table should be repeated.

Peritoneal dialysis

Ceftazidime may be used in peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD).

In addition to intravenous use, ceftazidime can be incorporated into the dialysis fluid (usually 125 to 250mg for 2 litres of dialysis solution).

For patients in renal failure on continuous arterio-venous haemodialysis or high-flux haemofiltration in intensive therapy units: 1 g daily either as a single dose or in divided doses. For low-flux haemofiltration, follow the dose recommended under renal impairment.

For patients on veno-venous haemofiltration and veno-venous haemodialysis, follow the dosage recommendations in the tables below.

Table 5: Continuous veno-venous haemofiltration dose guidelines

Residual renal function (creatinine clearance ml/min)

Maintenance dose (mg) for an ultrafiltration rate (ml/min) of1:

5

16.7

33.3

50

0

250

250

500

500

5

250

250

500

500

10

250

500

500

750

15

250

500

500

750

20

500

500

500

750

1 Maintenance dose to be administered every 12 h.

Table 6: Continuous veno-venous haemodialysis dose guidelines

Residual renal function (creatinine clearance in ml/min)

Maintenance dose (mg) for a dialysate in flow rate of 1:

1.0 litre/h

2.0 litre/h

Ultrafiltration rate (litre/h)

Ultrafiltration rate (litre/h)

0.5

1.0

2.0

0.5

1.0

2.0

0

500

500

500

500

500

750

5

500

500

750

500

500

750

10

500

500

750

500

750

1000

15

500

750

750

750

750

1000

20

750

750

1000

750

750

1000

1Maintenance dose to be administered every 12 h.

Method of administration

Fortum should be administered by intravenous injection or infusion, or by deep intramuscular injection. Recommended intramuscular injection sites are the upper outer quadrant of the gluteus maximus or lateral part of the thigh. Fortum solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids.

The standard recommended route of administration is by intravenous intermittent injection or intravenous continuous infusion. Intramuscular administration should only be considered when the intravenous route is not possible or less appropriate for the patient.

The dose depends on the severity, susceptibility, site and type of infection and on the age and renal function of the patient.


Go to top of the page
4.3 Contraindications

Hypersensitivity to ceftazidime, to any other cephalosporin or to any of the excipients.

History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).


Go to top of the page
4.4 Special warnings and precautions for use

As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with ceftazidime must be discontinued immediately and adequate emergency measures must be initiated.

Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftazidime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if ceftazidime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.

Ceftazidime has a limited spectrum of antibacterial activity. It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a very high suspicion that the most likely pathogen(s) would be suitable for treatment with ceftazidime. This particularly applies when considering the treatment of patients with bacteraemia and when treating bacterial meningitis, skin and soft tissue infections and bone and joint infections. In addition, ceftazidime is susceptible to hydrolysis by several of the extended spectrum beta lactamases (ESBLs). Therefore information on the prevalence of ESBL producing organisms should be taken into account when selecting ceftazidime for treatment.

Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all anti-bacterial agents, including ceftazidime, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftazidime (see section 4.8). Discontinuation of therapy with ceftazidime and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.

Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function.

Ceftazidime is eliminated via the kidneys, therefore the dose should be reduced according to the degree of renal impairment. Patients with renal impairment should be closely monitored for both safety and efficacy. Neurological sequelae have occasionally been reported when the dose has not been reduced in patients with renal impairment (see section 4.2 and 4.8).

Prolonged use may result in the overgrowth of non-susceptible organisms (e.g. Enterococci, fungi) which may require interruption of treatment or other appropriate measures. Repeated evaluation of the patient's condition is essential.

Ceftazidime does not interfere with enzyme-based tests for glycosuria, but slight interference (false-positive) may occur with copper reduction methods (Benedict's, Fehling's, Clinitest).

Ceftazidime does not interfere in the alkaline picrate assay for creatinine.

The development of a positive Coombs' test associated with the use of ceftazidime in about 5% of patients may interfere with the cross-matching of blood.

Important information about one of the ingredients of Fortum:

1 g powder for solution for injection

Fortum 1 g contains 52 mg of sodium per vial.

This should be considered for patients who are on a controlled sodium diet.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been conducted with a probenecid and furosemide.

Concurrent use of high doses with nephrotoxic medicinal products may adversely affect renal function (see section 4.4).

Chloramphenicol is antagonistic in vitro with ceftazidime and other cephalosporins. The clinical relevance of this finding is unknown, but if concurrent administration of ceftazidime with chloramphenicol is proposed, the possibility of antagonism should be considered.


Go to top of the page
4.6. Pregnancy and lactation

Pregnancy

There are limited amounts of data from the use of ceftazidime in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).

Fortum should be prescribed to pregnant women only if the benefit outweighs the risk.

Breast-feeding

Ceftazidime is excreted in human milk in small quantities but at therapeutic doses of ceftazidime no effects on the breast-fed infant are anticipated. Ceftazidime can be used during breast-feeding.

Fertility

No data are available.


Go to top of the page
4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines (see section 4.8).


Go to top of the page
4.8 Undesirable effects

The most common adverse reactions are eosinphilia, thrombocytosis, phlebitis or thrombophlebitis with intravenous administration, diarrhoea, transient increases in hepatic enzymes, maculopapular or uticarcial rash, pain and/or inflammation following intramuscular injection and positive Coomb's test.

Data from sponsored and unsponsored clinical trials have been used to determine the frequency of common and uncommon undesirable effects. The frequencies assigned to all other undesirable effects were mainly determined using post-marketing data and refer to a reporting rate rather than a true frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The following convention has been used for the classification of frequency:

Very common ≥1/10

Common ≥1/100 and <1/10

Uncommon ≥1/1,000 and <1/100

Rare ≥1/10,000 and <1/1000

Very rare <1/10,000

Unknown (cannot be estimated from the available data)

System Organ Class

Common

Uncommon

Very rare

Unknown

Infections and infestations

 

Candidiasis (including vaginitis and oral thrush)

 

 

Blood and lymphatic system disorders

Eosinophilia

Thrombocytosis

Neutropenia

Leucopenia

Thrombocytopenia

 

Agranulocytosis

Haemolytic anaemia

Lymphocytosis

Immune system disorders

 

 

 

Anaphylaxis (including bronchospasm and/or hypotension) (see section 4.4)

Nervous system disorders

 

Headache

Dizziness

 

Neurological sequelae1

Paraesthesia

Vascular disorders

Phlebitis or thrombophlebitis with intravenous administration

 

 

 

Gastrointestinal disorders

Diarrhoea

Antibacterial agent-associated diarrhoea and colitis2 (see section 4.4)

Abdominal pain

Nausea

Vomiting

 

Bad taste

Heptobiliary disorders

Transient elevations in one or more hepatic enzymes3

 

 

Jaundice

Skin and subcutaneous tissue disorders

Maculopapular or urticarial rash

Pruritus

 

Toxic epidermal necrolysis

Stevens-Johnson syndrome

Erythema multiforme

Angioedema

Renal and urinary disorders

 

Transient elevations of blood urea, blood urea nitrogen and/or serum creatinine

Interstitial nephritis

Acute renal failure

 

General disorders and administration site conditions

Pain and/or inflammation after intramuscular injection

Fever

 

 

Investigations

Positive Coombs' test4

 

 

 

1There have been reports of neurological sequelae including tremor, myoclonia, convulsions, encephalopathy and coma in patients with renal impairment in whom the dose of Fortum has not been appropriately reduced.

2Diarrhoea and colitis may be associated with Clostridium difficile and may present as pseudomembranous colitis.

3ALT (SGPT), AST (SOGT), LHD, GGT, alkaline phosphatase.

4A positive Coombs test develops in about 5% of patients and may interfere with blood cross matching.


Go to top of the page
4.9 Overdose

Overdosage can lead to neurological sequelae including encephalopathy, convulsions and coma.

Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment (see sections 4.2 and 4.4)

Serum levels of ceftazidime can be reduced by haemodialysis or peritoneal dialysis.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Anti-bacterials for systemic use.

Third-generation cephalosporins ATC code: J01DD02

Mechanism of action

Ceftazidime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

PK/PD relationship

For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with in vivo efficacy has been shown to be the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of ceftazidime for individual target species (i.e. %T>MIC).

Mechanism of Resistance

Bacterial resistance to ceftazidime may be due to one or more of the following mechanisms:

• hydrolysis by beta-lactamases. Ceftazidime may be efficiently hydrolysed by extended-spectrum beta-lactamases (ESBLs), including the SHV family of ESBLs and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species

• reduced affinity of penicillin-binding proteins for ceftazidime

• outer membrane impermeability, which restricts access of ceftazidime to penicillin binding proteins in Gram-negative organisms

• bacterial efflux pumps.

Breakpoints

Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:

Organism

Breakpoints (mg/L)

 

S

I

R

Enterobacteriaceae

≤1

2-4

>4

Pseudomonas aeruginosa

≤81

-

>8

Non-species related breakpoints2

≤4

8

>8

S=Susceptible, I=Intermediate, R=Resistant

1The breakpoints relate to high dose therapy (2 g x 3).

2Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species not mentioned in the table or footnotes.

Microbiological Susceptibility

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of ceftazidime in at least some types of infections is questionable.

Commonly Susceptible Species

Gram-positive aerobes:

Streptococcus pyogenes

Streptococcus agalactiae

Gram-negative aerobes:

Citrobacter koseri

Escherichia coli

Haemophilus influenzae

Moraxella catarrhalis

Neisseria menigitidis

Proteus mirabilis

Proteus spp (other)

Providencia spp.

Species for which acquired resistance may be a problem

Gram-negative aerobes:

Acinetobacter baumannii£+

Burkholderia cepacia

Citrobacter freundii

Enterobacter aerogenes

Enterobacter cloacae

Klebsiella pneumoniae

Klebsiella spp (other)

Pseudomonas aeruginosa

Serratia spp

Morganella morganii

Gram-positive aerobes:

Staphylococcus aureus£

Staphylococcus pneumoniae££

Gram-positive anaerobes:

Clostridium perfringens

Peptococcus spp.

Peptostreptococcus spp.

Gram-negative anaerobes

Fusobacterium spp.

Inherently resistant organisms

Gram-positive aerobes:

Enterococci including Enterococcus faecalis and Enterococcus faecium

Listeria spp

Gram-positive anaerobes:

Clostridium difficile

Gram-negative anaerobes

Bacteroides spp. (many strains of Bacteroides fragilis are resistant).

Others:

Chlamydia spp

Mycoplasma spp

Legionella spp

£S.aureus that is methicillin-susceptible are considered to have inherent low susceptibility to ceftazidime. All methicillin-resistance S. Aureus are resistant to ceftazidime.

££S.pneumoniae that demonstrate intermediate susceptibility or are resistant to penicillin can be expected to demonstrate at least reduced susceptibility to ceftazidime.

+High rates of resistance have been observed in one or more areas/countries/regions within the EU.


Go to top of the page
5.2 Pharmacokinetic properties

Absorption

After intramuscular administration of 500 mg and 1 g of ceftazidime, peak plasma levels of 18 and 37 mg/l respectively are achieved rapidly. Five minutes after intravenous bolus injection of 500 mg, 1 g or 2 g, plasma levels are 46, 87 and 170mg/l, respectively. The kinetics of ceftazidime are linear within the single dose range of 0.5 to 2 g following intravenous or intramuscular dosing.

Distribution

The serum protein binding of ceftazidime is low at about 10%. Concentrations in excess of the MIC for common pathogens can be achieved in tissues such as bone, heart, bile, sputum, aqueous humour, synovial, pleural and peritoneal fluids. Ceftazidime crosses the placenta readily, and is excreted in the breast milk. Penetration of the intact blood-brain barrier is poor, resulting in low levels of ceftazidime in the CSF in the absence of inflammation. However, concentrations of 4 to 20 mg/l or more are achieved in the CSF when the meninges are inflamed.

Biotransformation

Ceftazidime is not metabolised.

Elimination

After parenteral administration plasma levels decrease with a half-life of about 2 h. Ceftazidime is excreted unchanged into the urine by glomerular filtration; approximately 80 to 90 % of the dose is recovered in the urine within 24 h. Less than 1 % is excreted via the bile.

Special patient populations

Renal impairment

Elimination of ceftazidime is decreased in patients with impaired renal function and the dose should be reduced (see section 4.2).

Hepatic impairment

The presence of mild to moderate hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days, provided renal function was not impaired (see section 4.2).

Elderly

The reduced clearance observed in elderly patients was primarily due to age-related decrease in renal clearance of ceftazidime. The mean elimination half-life ranged from 3.5 to 4 hours following single or 7 days repeat BID dosing of 2 g IV bolus injections in elderly patients 80 years or older.

Paediatric population

The half-life of ceftazidime is prolonged in preterm and term neonates by 4.5 to 7.5 hours after doses of 25 to 30 mg/kg. However, by the age of 2 months the half-life is within the range for adults.


Go to top of the page
5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeat dose toxicity, genotoxicity, toxicity to reproduction. Carcinogenicity studies have not been performed with ceftazidime.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Sodium carbonate (anhydrous sterile)


Go to top of the page
6.2 Incompatibilities

Ceftazidime is less stable in Sodium Bicarbonate Injection than other intravenous fluids. It is not recommended as a diluent.

Ceftazidime and aminoglycosides should not be mixed in the same giving set or syringe.

Precipitation has been reported when vancomycin has been added to ceftazidime in solution. It is recommended that giving sets and intravenous lines are flushed been administration of these two agents.


Go to top of the page
6.3 Shelf life

Three years when stored below 25°C and protected from light.

Two years for Fortum Monovials when stored below 30°C and protected from light.


Go to top of the page
6.4 Special precautions for storage

The unconstituted product should be stored below 25°C and protected from light. Constituted solutions may be stored in the refrigerator (2 - 8°C) for up to 24 hours.


Go to top of the page
6.5 Nature and contents of container

Individually cartoned vials containing 1g ceftazidime (as pentahydrate) for intramuscular or intravenous use in packs of 1 or 5.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

All sizes of vials of Fortum are supplied under reduced pressure. As the product dissolves, carbon dioxide is released and a positive pressure develops. Small bubbles of carbon dioxide in the constituted solution may be ignored.

Instructions for constitution

See table for addition volumes and solution concentrations, which may be useful when fractional doses are required.

Vial size

 

Amount of diluent to be added (ml)

Approximate concentration (mg/ml)

250 mg powder for solution for injection

250 mg

Intramuscular

Intravenous bolus

1.0 ml

2.5 ml

210

90

500 mg powder for solution for injection

500mg

Intramuscular

Intravenous bolus

1.5 ml

5 ml

260

90

1 g powder for solution for injection or infusion

1 g

Intramuscular

Intravenous bolus

Intravenous infusion

3 ml

10 ml

50 ml*

260

90

20

2 g powder for solution for injection or infusion

2 g

Intravenous bolus

Intravenous infusion

10 ml

50 ml*

170

40

3 g powder for solution for injection or infusion

3 g

Intravenous bolus

Intravenous infusion

15 ml

75 ml*

170

40

*Note: Addition should be in two stages.

Solutions range in colour from light yellow to amber depending on concentration, diluents and storage conditions used. Within the stated recommendations, product potency is not adversely affected by such colour variations.

Ceftazidime at concentrations between 1 mg/ml and 40 mg/ml is compatible with:

• sodium chloride 9 mg/ml (0.9%) solution for injection

• M/6 sodium lactate injection

• compound sodium lactate injection (Hartmann's solution)

• 5% dextrose injection

• 0.225% sodium chloride and 5% dextrose injection

• 0.45% sodium chloride and 5% dextrose injection

• 0.9% sodium chloride and 5% dextrose injection

• 0.18% sodium chloride and 4% dextrose injection

• 10% dextrose injection

• Dextran 40 injection 10% in 0.9% sodium chloride injection

• Dextran 40 injection 10% in 5% dextrose injection

• Dextran 70 injection 6% in 0.9% sodium chloride injection

• Dextran 70 injection 6% in 5% dextrose injection

Ceftazidime at concentrations between 0.05 mg/ml and 0.25 mg/ml is compatible with Intra-peritoneal Dialysis Fluid (Lactate).

Ceftazidime may be constituted for intramuscular use with 0.5% or 1% Lidocaine Hydrochloride Injection.

:

Preparation of solution for bolus injection

1. Insert the syringe needle through the vial closure and inject the recommended volume of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.

2. Shake to dissolve: carbon dioxide is released and a clear solution will be obtained in about 1 to 2 minutes.

3. Invert the vial. With the syringe plunger fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). Ensure that the needle remains within the solution and does not enter the head space. The withdrawn solution may contain small bubbles of carbon dioxide; they may be disregarded.

These solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids. Ceftazidime is compatible with the most commonly used intravenous fluids.

Any unused product or waste material should be disposed of in accordance with local requirements.


Go to top of the page
Administrative data

Go to top of the page
7. Marketing authorisation holder

Glaxo Operations UK Ltd

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Trading as

GlaxoSmithKline UK

Stockley Park West

Uxbridge

Middlesex UB11 1BT


Go to top of the page
8. Marketing authorisation number(s)

PL 00004/0293


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

18 May 2001


Go to top of the page
10. Date of revision of the text

14 June 2013



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/19176/SPC/


Active Ingredients/Generics